This systematised review of 82 sources synthesised published guidance on substances, dosages, session structure, music and in-session therapeutic conduct for administration sessions with serotonergic psychedelics and entactogens. It concludes that evidence is largely anecdotal and non-rigorous, leaving essential components of therapeutic interventions tentative and in need of systematic empirical investigation.
While the potential of serotonergic psychedelics and related substances as adjuncts in substance-assisted psychotherapy (SAPT) has been investigated for the treatment of several disorders, evidence for the appropriate therapeutic conduct in administration sessions is sparse. In this article, we discuss the current evidence for best therapeutic practice during administration sessions with serotonergic psychedelics and entactogens as adjuncts to psychotherapy. We conducted a systematized review of the literature following PRISMA guidelines. PsycINFO, MEDLINE, and Cochrane Library databases were searched. Clinical trials, treatment manuals, study protocols, qualitative studies, case studies, descriptive studies, opinion papers, reviews, book chapters, and conference proceedings published until February 1, 2022 were retrieved. The final synthesis included k = 82 sources. Information about substances, dosages, number of administration sessions, issues that are common for clients, different types of experiences, music, and therapeutic conduct was summarized, compared, and critically discussed. The effects different therapeutic models, methods, techniques, and more complex interventions each have on the therapeutic outcome have not been investigated by means of rigorous research. Most of the available evidence we retrieved was anecdotal limiting any conclusive statements regarding appropriate therapeutic conduct during administration sessions. Consequently, essential components of therapeutic interventions remain largely tentative, necessitating systematic investigation.
Papers cited by this study that are also in Blossom
Alper, K. R., Lotsof, H. S., Frenken, G. M. N. et al. · The American Journal on Addictions (2010)
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S. et al. · Journal of Psychopharmacology (2016)
Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)
Slevc, L. R., Barrett, F. S., Robbins, H. et al. · Frontiers in Psychology (2017)
Psychedelics have a long anthropological history and renewed contemporary interest across ritual, recreational, underground therapy and clinical settings. Thal and colleagues note that while several serotonergic psychedelics and entactogens (for example psilocybin, LSD, ayahuasca, MDMA) are being investigated as adjuncts to psychotherapy for conditions such as addiction, anxiety, obsessive–compulsive disorder and treatment‑resistant depression, guidance about how therapists should conduct the administration session itself remains sparse. The authors highlight that therapeutic outcomes in substance‑assisted psychotherapy (SAPT) are shaped by the pharmacology of the substance, client dispositions and subjective experiences during dosing, and by preparatory and integration work, yet practical detail about in‑session conduct is often anecdotal or under‑reported in modern trials. This systematised review aims to summarise reported practices for the administration stage of SAPT. Specifically, Thal and colleagues set out to extract information about which substances are used as adjuncts, typical dosages, the number of administration sessions across models, common client and therapist issues during dosing, the types of subjective experiences elicited, and recommended therapeutic conduct during administration sessions. The paper is positioned as the third in a series synthesising Western psychotherapeutic paradigms for SAPT developed since the 1950s, building on prior reviews of preconditions and preparation-stage practices.
Thal and colleagues conducted a systematised literature review following PRISMA 2020 guidance and focused on extracting qualitative details rather than performing quantitative meta‑analysis. They searched MEDLINE (OVID), PsycINFO (OVID) and the Cochrane Library for publications available before 1 February 2022, supplemented these searches by scanning reference lists and consulting field experts, and archived search strings on an Open Science Framework page. Retrieved records were managed in EndNote 20. Inclusion criteria were broad: studies needed to involve classic serotonergic psychedelics or MDMA as adjuncts in SAPT, incorporate a psychotherapy or therapeutic technique, describe methods or theory guiding therapist conduct, and recruit participants diagnosed with psychiatric disorders per DSM‑IV or ICD criteria. After initial screening, the team also included healthy‑participant dosing studies that explicitly investigated dose effects. Exclusions comprised in vitro or animal research, indigenous/ritualistic uses, subperceptual dosing, unavailable full text, language other than English or German, and multi‑substance combinations. The review encompassed diverse document types (clinical trials, manuals, protocols, case studies, qualitative and descriptive papers, opinion pieces, reviews and book chapters). Screening was performed by pairs of independent reviewers in two waves (initial search 1 July 2019 and a repeat search 1 February 2022). Interrater reliability for title/abstract and full‑text screening was reported as good to excellent across rounds (κ values reported as 0.72, 0.66, 0.76 and 0.90). Data extracted from eligible sources included clinical targets, study design, therapeutic framework, substances and doses administered, and number of administration sessions; the reviewers synthesised this information to describe current best‑practice approaches for administration sessions.
The combined searches yielded a large literature base. The first search produced 3,932 hits plus 45 secondary records; after duplicate removal and screening 88 sources were included from that round. The second search returned 6,619 hits; after removing 447 duplicates and screening 6,172 records, 224 full texts were assessed and, with added records and one article included after peer review, the final synthesis comprised 82 publications. The 82 included items were heterogeneous in type: 31 clinical trials, one follow‑up analysis, four treatment manuals, two study protocols, three quasi‑experiments, two case studies, three qualitative investigations, three descriptive studies, one time‑series study, 14 opinion papers, 11 reviews, and seven books or book chapters. Not every source addressed all review questions. Substances and dosing: Psilocybin doses in recent clinical trials ranged from 1.75 to 30 mg with a median of 21 mg (reported as based on an average 70 kg body weight). A post hoc analysis of 10 studies (n = 288) reported moderately high mystical and intensity scores at 20 mg/70 kg and high mystical/intensity scores at 30 mg/70 kg, with similar low–moderate challenging‑experience scores; that analysis found no advantage to bodyweight‑adjusted dosing over fixed dosing. LSD historical dosing has ranged widely (20 μg to 1,500 μg) with a recent trial using 200 μg; some sources consider 100–200 μg therapeutically optimal in healthy adults. Ayahuasca was reported in one clinical study with specified alkaloid concentrations and dosing of 0.36 mg/kg N,N‑DMT. MDMA doses in clinical work ranged from 50 to 125 mg (commonly with a booster ≈50% of the initial dose offered after 2 hr) and a median dose of 110 mg; plasma MDMA concentration (and thus subjective strength) is significantly influenced by dose per bodyweight, leading to recommendations to adjust MDMA dosing for bodyweight. The authors note that dose selection should consider substance recommendations, client intentions and prior responses. Number of sessions: Historical models included a high‑dose single‑session psychedelic model, multi‑session escalating‑dose models, and low‑dose psycholytic approaches (the latter sometimes involving many sessions, up to 80). Contemporary clinical studies generally used between one and four administration sessions with a median of two; the chosen model influenced session counts. Commencing sessions and practicalities: Day‑of protocols commonly include a brief mood/well‑being check, cancellation if illness is present, a review of intentions and practical procedures (for example bathroom, agreements on touch), and a final reassessment of dose/substance. Many protocols encourage pre‑session silence, meditation or prayer to aid surrender; clients are often invited to self‑administer the dose, lie down and adopt an inward focus. Therapists are advised to trust their judgment and decline sessions if uncertain. Music: Music is widely used through headphones and is described as shaping subjective experience and possibly therapeutic outcome. Reported effects include facilitation of peak experiences, emotional release and autobiographical processing, but music can also have unwelcome effects (misguidance, negative intensification). Empirical findings are mixed: an early LSD study (n = 49) found no music‑condition differences, whereas a small psilocybin study reported overtone‑based music increased mystical scores and marginally improved treatment response relative to Western classical music. Expert surveys and interviews have been used to compile recommended pre‑peak and peak playlists and six key criteria proposed for effective music use, but definitive evidence for curated versus personalised playlists or specific genres is lacking. Client experiences and common issues: The review summarises a typology of experiences reported across sources—sensory‑aesthetic, psychodynamic‑autobiographical, cognitive‑intellectual, symbolic‑archetypal, challenging, and mystical. Challenging experiences (anxiety, panic, dissociation, paranoia etc.) and adverse physiological reactions vary by substance and dose; clinicians are advised to validate distress, provide reassurance, use grounding techniques (breathing, guided imagery, music changes), and reserve anxiolytics or antipsychotics for severe escalation. Mystical or peak experiences (ego dissolution, unity, noetic quality) are reported as reliably occasioned by classic psychedelics in prepared settings and have been associated in some randomised trials with persisting clinical benefits; they are proposed as potential mediators of therapeutic efficacy. Therapeutic conduct: Across sources, an unobtrusive, supportive and largely nondirective stance during administration sessions is recommended, with therapists ensuring physiological and psychological safety, minimising intrusive intervention, and preserving the client's inward focus. Presence, self‑awareness and responsiveness from therapists are emphasised, although these constructs have not been systematically measured in SAPT. Use of mixed‑gender co‑therapist teams is common to reduce therapist exhaustion. Conventional psychotherapeutic techniques (for example CBT, motivational enhancement, ACT) are more often used in preparation and integration, while verbal interventions during peak effects are limited; in psilocybin protocols, structured techniques are generally withheld until the final hour. Physical contact can be supportive when pre‑agreed and non‑sexual, but the literature flags increased risk of boundary violations under suggestibility. Projection, transference and countertransference may be amplified in SAPT; authors recommend supervision and preparation to manage these phenomena, though evidence is anecdotal. Practical conclusion procedures include creative expression and encouragement of reflection; overnight observation or hospitalisation is advised if severe anxiety or suicidality persists.
Thal and colleagues conclude that while there is broad consensus in the literature for an unobtrusive, supportive therapist stance during administration sessions, the empirical foundation for specific in‑session practices is weak. Much of the available guidance derives from anecdote, early (pre‑1970) research and descriptive sources, and modern clinical trials frequently do not report detailed information about how administration sessions were conducted. Consequently, the authors argue there is a pressing need for timely, rigorous qualitative and quantitative research to evaluate how specific therapeutic conduct during dosing affects outcomes and to clarify mechanisms of action. Several specific gaps are highlighted: validation of optimal substance–dose combinations for particular disorders; investigation of ethnoracial and sex differences in metabolism, safety and efficacy (given underrepresentation of women and Black, Indigenous and People of Colour in current samples); examination of derivative compounds; empirical determination of optimal numbers of administration sessions; and better evidence about the role and ideal sequencing or personalisation of music. The authors call for studies that link the occurrence and intensity of particular experiential classes to clinical outcomes and for research into the influence of therapist characteristics such as presence, responsiveness and self‑awareness, for which measurement instruments exist but have not been applied in SAPT. The discussion also stresses the difficulty of disentangling psychopharmacological effects from psychotherapeutic components and suggests experimental comparisons—such as nondirective supportive contexts versus manualised CBT frameworks, or systematic variation of psychotherapy elements across preparation, administration and integration—would be informative. Practical clinical priorities include comparing techniques used to de‑escalate distress (for example breathing, holding hands, anxiolytics) and investigating projection/transference management. The authors further note concerns about therapeutic misconduct and boundary violations in SAPT settings due to client suggestibility, recommending regulatory scrutiny, supervision, repeated training and formalised safeguards to reduce the risk of unethical behaviour. In sum, the authors state that although SAPT clinical research is advancing, essential components of therapeutic interventions during administration sessions remain tentative and largely untested; therefore conclusive best‑practice statements are not yet possible. They propose that the comprehensive description provided can inform baseline structures for training programmes and guide future systematic investigations into how in‑session practices and client experiences influence therapeutic outcomes.
It is suggested that people have consumed psychedelics for at least 5,700 years. The use of psychedelics in the general population is increasingand the contexts these substances are currently consumed in range from ritualistic, shamanistic, and indigenous contexts, to recreational use in festival settings, to underground therapyand clinical studies with and without psychological support and/or psychotherapy. Evidently, the field is experiencing a surge of interest, and with it a growing need for guidance. However, there are limited data to draw firm conclusions about how to handle administration sessions. In the current article, we aim to summarize the reported suggested practices during administration sessions of substance-assisted psychotherapy (SAPT) to date, to inform subsequent work and to offer practitioners an overview of common practices in the field. Following the resumption of research into the therapeutic application of psychedelics, various substances have been investigated as potential adjuncts in SAPT. Serotonergic or "classic" psychedelics, which were mainly used in the treatment of alcohol dependence, have now also been effectively used for the treatment of existential anxiety (e.g.,, tobacco dependence, alcohol dependence, obsessive-compulsive disorder, and treatment-resistant depression (e.g.,. Meanwhile, 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine have been used for the treatment of opioid dependence (e.g.,, depression, post-traumatic stress disorder, and social anxiety disorder. The mechanisms responsible for the effectiveness of these substances in therapeutic settings across psychiatric disorders are not fully understood. Therapeutic outcomes are affected by the psychopharmacological effects of the substance (see, the client's dispositions, their subjective experience, emotional breakthroughs during the administration sessions and psychological insights after the experience, and the successful integration of the experience into their lives. Some of the acute substance-induced subjective experiences that may be linked to positive outcomes include ego dissolution, mysticomimetic experiences (i.e., mimicking mystical experiences;, and death transcendence. Challenging experiences, or more precisely, their quality, intensity, and duration may also mediate the therapeutic outcome. Furthermore, different psychotherapeutic approachesand therapy-related variables, as well as contextual factors (see, are thought to influence the outcome of the SAPT. The course of SAPT may be divided into three stages: the preparatory stage, the administration stage, and the integration stage. Careful consideration of all aspects constituting each of these stages is important as preparation before administration of the substances, the shared interpersonal experience between client and therapist, and subsequent integration of the experiencemay affect the outcome of SAPT. In this article, we review the current evidence for best therapeutic practice during administration sessions with classic psychedelics and entactogens as adjuncts to psychotherapy. This article is the third in a series of papers reviewing the literature on Western psychotherapeutic paradigms of SAPT that have been developed and employed since the 1950s. The first paper in this seriesoutlined the appropriate preconditions for conducting SAPT including ethical considerations, the spiritual emphasis of the therapeutic approaches, different concepts of psychological mechanism of action and therapeutic effects of SAPT, and similarities between models, approaches, and potential mediators for therapeutic effects. The second paperdiscussed best practice measures for appropriate therapeutic conduct in preparation sessions to provide a basis for future investigations and training programs for therapists. This included current safety and screening procedures; set and setting; contextual-, physiological-, and psychological preparation; prerequisites of the therapists; and the importance of the therapeutic relationship. The purpose of the current review is to identify, analyze, and discuss current literature to inform therapeutic conduct during the administration stage of SAPTs. Thereby, we aimed to extract details regarding (a) substances that are used as adjuncts in SAPT, (b) dosages that are used in SAPT, (c) number of administration sessions that are used across different models of SAPT, (d) common issues for clients and therapists, (e) common types of experiences, and (f) therapeutic conduct during administration sessions in SAPT.
We followed PRISMA 2020 guidelinesand conducted a systematized review of the literature. We did not consider quantitative analyses informative since the objective of this review was to extract qualitative study details to describe current best-practice methods. We systematically searched the MEDLINE (OVID), PsycINFO (OVID), and Cochrane Library databases and included papers that were published before February 1, 2022. We published detailed information about the search strings for the respective databases on the project's Open Science Framework (OSF) page (). We scanned references of retrieved articles and consulted experts in the field to supplement our search. Finally, we imported the literature into EndNote 20.
We selected broad inclusion criteria because we expected the literature outlining administration of psychedelics to be sparse. We included studies that (a) used classic psychedelics or MDMA in SAPT, (b) used a type of psychotherapy or therapeutic techniques as part of an intervention, (c) described the methods and/or theories used for administration and to guide the conduct of therapists, and (d) recruited participants diagnosed with psychiatric disorders according to Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; American Psychiatric Association [APA], 1994),, or International Classification ofcriteria. We excluded studies if they (a) involved in vitro research, (b) involved animal research, (c) described indigenous and ritualistic use, (d) the administered doses in the intervention condition were subperceptional, (e) the full text was unavailable via institutional access or through direct correspondence with the authors, or (f) were written in any language other than English or German. After reviewing the literature, we decided to also include studies with healthy participants (i.e., who did not have a psychiatric diagnosis) that explicitly investigated the effects of different doses of substances to provide a complete picture of the dosages that are currently used in clinical research. We limited our review to individual and couples therapy but aimed to synthesize applicable and valuable insights from literature regarding group therapy. We further disregarded the use of combinations of two or more psychoactive substances. Detailed information regarding excluded studies is outlined on the project's OSF page (). The final sources consisted of clinical trials and follow-ups, treatment manuals, study protocols, case studies, qualitative studies, descriptive studies, theoretical papers, reviews, book chapters, and conference proceedings. We expected that not every resource would provide information relevant to all aspects that we hoped to cover in this review to an equal degree.
Two independent reviewers (S.B.T. and T.W.) screened the retrieved literature for the initial search on July 1, 2019. Good interrater reliability was reached (κ = 0.72;for the title and abstract screening. In a subsequent full-text review, good interrater reliability was reached (κ = 0.66;. We conducted a second search with an identical search string on February 1, 2022. Two independent reviewers (S.B.T. and M.W.) screened the title and abstract reaching good interrater reliability (κ = 0.76;. In the subsequent full-text review, excellent interrater reliability (κ = 0.90;was reached. If sources were identified as suitable for inclusion by one reviewer but not the other in either search, the suitability of the literature was discussed with the other co-authors until a consensus was reached.
We extracted data from eligible studies including details on the type of clinical target, study design, therapeutic framework, substance administered, dosage administered, and number of administration sessions. We then synthesized the retrieved information regarding current best-practice approaches in administration sessions.
The terminology used in the literature varies widely.identified the term "therapist(s)" to be the preferred terminology by psychedelic scholars used for the person(s) conducting the session(s). Consequently, we use this expression in this article. Furthermore, we use the term "client" to maintain a professional reference and avoid pathological connotations.
The first search resulted in 3,932 hits. In addition, 45 records were identified through secondary sources. After preliminary analysis of the titles and abstracts, a total of 390 duplicates were removed and 136 sources were identified for further full-text analyses. In the initial search, 88 sources were included through consensus. The subsequent search resulted in 6,619 hits. The EndNote 20 software was used to remove 447 duplicates. The remaining 6,172 sources were screened by title and abstract. Consequently, 5,948 sources were exclusions, and 224 full-text publications were identified for full-text analysis by two independent reviewers (S.B.T., M.W.). Afterward, 22 additional articles and book chapters were included. In addition, one article was included after the peer review with the result that 82 papers, and book chapters were included in the final results (see Figure). As expected, not every resource was able to speak to each issue discussed below.
The details of the publications included in the final qualitative synthesis can be found in Supplemental Appendix A. The 82 publications included 31 clinical trials, one follow-up analysis, four treatment manuals, two study protocols, three quasi experiments, two case studies, three qualitative investigations, three descriptive studies, one time-series study, 14 opinion papers, 11 reviews, and seven books and book chapters.
Psilocybin is considered a classic psychedelic and is found in more than 200 species of mushrooms. The effects of psilocybin are usually noticeable 10 to 40 min after ingestion, and last 2 to 6 hr depending on the dose and individual metabolism. Doses of psilocybin in recent clinical trials ranged from 1.75 to 30 mg with 21 mg being the median dose used (based on an average body weight of 70 kg; see Supplemental Appendix A). A post hoc analysis of 10 studies with 288 participants showed that, on average, participants who received 20 mg/70 kg reported moderately high scores for mystical experiences and intensity and low to moderate scores for challenging experiences. Participants who received 30 mg/70 kg reported, on average, high scores for mystical experiences and intensity and low to moderate scores for challenging experiences. The same study showed no advantage of adjusting the dosing of psilocybin to the bodyweight of participants over fixed dosing. Lysergic acid diethylamide (LSD) is a lysergamide derived from alkaloids of a group of fungi known as ergot. The effects of LSD may last up to 12 hr. In the past doses have ranged from 20 μgto 1,500 μg. The only recent clinical study administered a dose of 200 μg. Some authors consider optimal therapeutic effects be achieved in the range of 100 to 200 μgamong healthy adults, with 100 μg being considered an "intermediate" or "good effect" dose (i.e., a good combination of positive subjective effects and medium levels of ego dissolution with minimal negative subjective effects), and 200 μg being considered a "high" or "ego dissolution" dose (i.e., substantial ego dissolution, similar positive subjective effects but increased negative subjective effects;. Sex and bodyweight do not seem to affect the plasma concentration or subjective strength of effects for LSD in healthy participants. Ayahuasca is commonly preparedby combining Psychotria viridis and Banisteriopsis caapi. Its effects last for 4 hr. The ayahuasca used in the only clinical study to datecontained 0.36 mg/mL of N,Ndimethyltryptamine (N,N-DMT), 1.86 mg/mL of harmine, 0.24 mg/mL of harmaline, and 1.20 mg/mL of tetrahydroharmine and participants received ayahuasca adjusted to contain 0.36 mg/kg of N,N-DMT. MDMA is usually classified as an entactogen (i.e., producing feelings of empathy and connection;. Subjective effects commonly peak after 2 hr and last around 4 hr. Doses administered in clinical studies ranged from 50 to 125 mg (usually with a booster of 50% of the initial dose offered after 2 hr) with 110 mg being the median dose (see Supplemental Appendix A). The best predictor of the subjective strength of MDMA's effects is plasma MDMA concentration, which is significantly dependent on the dose per body weight someone receives. Thus, it has been recommended to consider dose adjustments for bodyweight. The dosage of the substance(s) affects the strength of the subjective effects of the experience. It was suggested that the ideal dosage should be determined considering the recommended amounts for a specific substance, the client's intentions, and the client's past reactions to the substance. Substances and doses employed in current clinical trials are outlined in detail in Supplemental Appendix A.
Historically, a high-dose single-session Psychedelic model was preferred (for review see. Alternatively, multiple sessions with escalating doses were used, or a booster dose was offered a few hours after the initial dose was administered. In the case of the low-dose Psycholytic model, up to 80 substance-assisted sessions were conducted throughout the course of therapy, although some therapists argued that psychoactive substances be used as sparingly as possible as adjuncts to psychotherapy. The number of administration sessions that have been used in recent clinical studies has ranged between one and four sessions with a median of two sessions (see Supplemental Appendix A). The number of administration sessions may depend on the model that is used for the treatment (see.
Information about proper preparation and safety measures is outlined in our earlier article. On the day of the substance-assisted session, protocols usually have the therapist(s) check-in with the client to briefly assess their overall mood and well-being (e.g.,. If the client reports feeling unwell or exhibits signs of a potential illness, the session might be canceled or postponed. A certain degree of pre-emptive anxiety and excitement may, however, be normal and widely reported. Expectations and intentions might be reviewed and clients may be shown the location of the bathroom and the restroom procedure. Current treatment protocols suggest that the rationale behind the therapeutic approach, the range of experiences, and strategies and techniques for potentially challenging experiences should be reviewed before the substance is administered. Questions, fears, and doubts can be addressed prior to administration. The client may further be reminded of the agreements made during preparatory sessions regarding physical contact, self-harm, and harm to others and property. The appropriate dose and substance for the session may also be reassessed and discussed with the client. Anecdotal reports, self-reports, and treatment protocols suggest that silence, meditation, or even prayer before the administration of the substance can assist clients in their surrender to the experience. Some authors take the view that these preparatory activities aid in reducing anxiety prior to administration, throughout the session and afterward. Some current treatment protocols suggest offering the substance to the client in a designated vessel and instructing clients to take it of their own accord to promote active engagement and self-efficacy. After ingesting the substance, clients are usually invited to lie down and focus inward.advises therapists should trust their intuition and refuse to conduct the session if they do not feel certain about it.
Music is a consistent feature reported in SAPT studies (e.g.,, used for guidance and support. It is usually delivered through headphones and may significantly affect the subjective experience and the therapeutic outcome. There are also some reports that music may facilitate peak experiences, emotional release, and autobiographical processingand it is associated with mystical experiences and insights during administration sessions. Music may also reduce distraction from environmental stimuli and the urge to partake in verbal interactions. Furthermore, it may be a source of support and reassurance. Some consider music a source of nonverbal direction allowing for deep immersion into the experience. For the client, songs may become immersive worlds, and music may be experienced as a profound, highly personal, and dynamic element of the administration session.conducted semi-structured interviews with 19 participants who received psilocybin for treatment-resistant depression and found that music had both welcome (i.e., effects described as accepted, appreciated, and wanted) and unwelcome (i.e., effects described as rejected, unappreciated, and unwanted) effects on participants' subjective experience. Welcome influences included a sense of guidance, a sense of safety and calm, the evocation of therapeutically useful and personally meaningful emotions and mental images, perceived openness, and positive intensification of the experience. Unwelcome influences included perceived misguidance and resistance, the evocation of unpleasant imagery and emotion, and negative intensification of the experience. It is thus evident that music may have positive and negative influences on the subjective experience. Clinical guidelines often emphasize the importance of (Western classical) music during SAPT. Usually, it is recommended that the structure and time course of an administration session should match music sequencing). An early study with 49 participants found no significant differences in effects across no music, familiar music, and unfamiliar music conditions in people receiving LSD in the treatment of alcohol use disorder. More recently, overtone-based music (i.e., music in which instruments with a particularly strong overtone signature were prevalent) was found to elicit higher mystical experience scores and slightly higher treatment response compared with Western classical (similar to the music most commonly used in curated playlists in SAPT) music in a small sample of participants receiving psilocybin for tobacco smoking cessation.conducted an anonymous online survey with 10 individuals with extensive experience in administering psilocybin in therapeutic and/or research conditions. They identified 24 recommended musical stimuli that support the onset or pre-peak period of psilocybin effects and 24 recommended musical stimuli that may support peak effects of psilocybin based on the survey. Compared with pre-peak music, peak music comprises formulaic, regular, and predictable phrase structure and orchestration, a slowly building feeling of continuous forward motion, and lower perceptual brightness. Based on these findings, 27 titles for pre-peak and 27 titles for peak periods of administration sessions were recommended. It is currently not established whether curated playlists (as used by, personalized playlists (as used by, or specific genres of music offer therapeutic advantages. According to, six key criteria should be considered for the effective use of music in SAPT, including (a) type of direction provided by the music, (b) adaptation of the music to the session, (c) adaptation of the music to the current personal process of the client and potential musical resistance, (d) understanding and consideration of the role of silence, (e) preparation of an open mindset, (f) appropriate technical specification for the music delivery.
Diverse effects of psychoactive substances on the client were described, ranging from a feeling of complete alienation to a feeling of recalling and reuniting with a very familiar state of mind. It might be challenging to encounter these altered states and to accept the corresponding positive or difficult feelings without acting on them. The potential for adverse physiological reactions can depend on the substance and dose (see, for example,. Adverse psychological effects can generally include anxiety, panic, dysphoria, paranoia, isolation, dissociation, confusion, and delusion. These effects may even result in transient, and if handled inappropriately potentially permanent, psychological crisis. The previously mentioned pre-emptive fear may lead to attachment behaviors and dependence on the therapist(s) and/or the substance. For personal growth and positive treatment effects, self-regulation, staying with, and observing these fearful reactions are thought to be essential. As in regular psychotherapy, it is suggested that some clients may produce and talk about the material that they think is expected from them. This may be emphasized by certain substances (such as LSD) that can enhance suggestibility in clients. Due to the strong psychological effects of the substances used as adjuncts, memories may surface, and clients may experience emotional catharsis with the potential for abreaction and subsequent relief and remission. Preliminary and anecdotal evidence suggests that the risk of a traumatic experience may be avoided by clients gaining new perspectives and correcting patterns of emotional responses through previously inaccessible positive associations. It has been suggested that a prerequisite for this corrective process could be the client's ability to surrender to the experience and witness the resurfacing of difficult memories.
There was a common understanding across sources that the effects of psychoactive substances in SAPT may be difficult to predict. Garcia-Romeu andnote that the mere description of these typologies may impact subsequent experiences through expectations and suggestions. These authors further discourage valuing certain experiences over others and advise to equally acknowledge and accept the vast potential of different experiential encounters. Garcia-Romeu andfor alternate taxonomy) outline the following classes of experiences for low to medium doses of serotonergic psychedelics: sensory-aesthetic, psychodynamic-autobiographical, cognitive-intellectual, and symbolic-archetypal, challenging, and mystical experiences for high doses. Sensory-aesthetic experiences include perceptual changes across all senses. The role of these experiences in treatment outcomes has not been adequately examined since these experiences might be altered in clinical settings due to the common use of eyeshades, music, and the minimization of interpersonal communication. Psychodynamic-autobiographical experiences include recollection, reemergence or revisiting, and reflections on negative experiences regarding significant past or present autobiographic events and relationships. There is preliminary qualitative evidence that these experiences contribute to therapeutic efficacy. Cognitive-intellectual experiences refer to alterations of baseline cognitive patterns and thinking. While models of SAPT do not leverage these as part of the therapeutic process, some authors take the view that alterations of cognitive patterns and novel perspectives might challenge maladaptive schemas and allow spontaneous cognitive reframing. However, this has not been empirically examined. Symbolic-archetypical experiences are sometimes referred to as "visionary experiences" and involve symbolic content like historical imagery, gemstones, and encounters with deities and universal qualities such as beauty, truth, or love. There is anecdotal evidence for the therapeutic value of these experiences through reduced client anxiety and the rich material they can offer for continuous integration processes. Challenging experiences include fear, anxiety, panic, paranoia, confusion, disorientation, grief, isolation, and physical discomfort are generally linked to psychotomimetic reactions (i.e., psychotic experiences such as delusions) and a persistent fear of dying or going insane. Extensive preparation, adequate set and setting, social support, and a good therapeutic relationship all reduce the likelihood of challenging experiences (see. Regardless, clients may benefit from these experiencesprovided the therapist(s) remains calm, reassuring, present, emotionally responsive, and is able to assist the client integrate afterwards.recommends that the experience of the client should be validated, and the client should be reminded that they are safe and that the experience is temporary, normal, and related to the effects of the substance. Guided imagery or breathing exercises (the therapist(s) may breathe together with the client; Watts, 2021) and changes in music can be used to provide structure and containment. In doing so, it is hoped that clients will cease to resist and reject the experience, and instead accept and surrender to it. In extreme cases, anxiolytics and antipsychotics can be administered. Subsequent to a challenging session, the therapist(s) must monitor the client's emotional state. Intensive and timely recapitulation, reflection, and integration are considered especially important for the contextualization and meaning-making of the experience. Mystical experiences-also called peak or transcendent experiences, or ego dissolution-comprise a transcendence of time and space, intense positive mood, the feeling of unity, sacredness, ineffability, and a perception of ultimate truth and reality (i.e., the noetic quality;. These experiences can be reliably occasioned with classic psychedelics provided the set, setting, client, and therapist(s) are well-prepared. As outlined above, mystical experiences have been linked to persisting personality changes, and anxiolytic, antidepressant, and antiaddictive effects in several randomized controlled trials. Mystical experiences may thus be a mediating factor for the therapeutic efficacy of SAPT (Garcia-Romeu & Richards, 2018). However, these experiences can also pose challenges to the study of psychedelics that are outlined elsewhere.
The literature revealed several issues that may present challenges to the therapist's skill and resources. This includes reports that the intensity and duration of the session can be quite exhausting for therapists, and over-exhaustion or feeling drained of energy, perspective, and compassion is unhelpful. It is suggested that this can be prevented by making the session as comfortable as possible for the client and the therapist(s). Using a co-therapist team can also ease exhaustion. In most contemporary studies, a mixed-gender co-therapist team is used (see. Non-Directiveness and Support. Most reviewed sources described that the therapist(s) must ensure the physiological and psychological safety of the client and minimize the potential for difficulties and adverse reactions. This may in turn create the conditions for the emergence of transcendent, transpersonal, and mystical states. Most sources recommend that the therapist(s) avoids intruding into the client's process and allows room for the effect of the substances to unfold, sometimes subtly reminding clients of their goals and focus: to go inside, surrender to the experience, trust, and let go. If previously agreed upon with the client, the therapist(s) might guide the client toward the core themes (e.g., their index trauma) of their therapeutic processes. Even though many recent studies applied therapeutic frameworks to SAPT that were not nondirectional, per se (k = 11 explicitly used nondirectional/supportive frameworks; see Supplemental Appendix A), there is usually very limited verbal (psychotherapeutic) interaction in administration sessions across frameworks. Moreover, it has been noted that being present can often be of more value to clients than verbal exchange. Across all sources, there was a consensus that therapists should let the transpersonal experience unfold during the session to let the client stay with their own realizations, encourage them to collect and remember their experiences, offer reassurance, and save the discussion for later review and reflection instead of offering interpretation and suggestions or intrude on the client with their ideas or opinions during the session. The therapist(s) may both construct and retain the framework for the session and avoid trying to excessively control its course. The therapist(s) may assist the clients to the bathroom, help them with the ingestion of liquids or food, or change the music for them. Self-Awareness, Presence, and Responsiveness.suggest that the therapist(s) remains responsible for their own feelings, stance and attitude, the client, and what happens in the shared space. This includes their own potential feelings of anxiety, fear, or boredom while modeling an open attitude and interest toward clients. Moreover, the therapist(s) may pay attention to their intuition, motivation, behavior, and mindset. Maintaining a patient, thorough, and friendly attitude is thought to be helpful. The importance of the presence of the therapist(s) has been consistently alluded to in the literature that was retrieved for this article. Therapeutic presence may be defined as a state of being nonjudgmental, receptive, gentle, and compassionate to the experiences of the clientand is closely linked to a person-centered approach and Roger's idea of the importance of presence, congruence, positivity, acceptance, and empathy from the therapist(s) in the context of psychotherapy, outlined above. Therapeutic presence is thought to be essential for effective therapeutic relationships, independent of the approach or theoretical orientation of the therapist(s). Nevertheless, the concept of therapeutic presence has not yet been qualitatively or quantitatively assessed and investigated in the context of SAPT. Some consider the therapists' emotional and physical responsiveness and alertness crucial due to the potential sudden shifts in the mental states of the client and the content of their experiences. Meanwhile, the therapists' presence may maintain a nonintrusive quality.recommends that therapists be constantly present; if clients appear to be engaged, they may do nothing. If clients are not engaged, they may communicate with them and check for potential resistance. While the therapist(s) may respond to the physical and emotional needs of the client and, if requested, may offer perspective, significant psychotherapeutic work is generally avoided until the effects of the substance have ceased. Some clients may become demanding, especially during regressive processes, while others may grow distrustful and paranoid. The therapist(s) must be able to work with a variety of emotional responses and not react to or engage with clients in an unhealthy way. Physical contact and touch might be helpful and supportive-some have even described it as essential-if previously discussed and agreed upon with the client. However, it is noted that the potential for gross exaggerations of the client's imagination during the session requires careful awareness of intended and unintended physical contact from the therapist.explicitly stress that if the client's experience is negative and there are obvious signs of anxiety or distress, therapists should empathize with the situation of the client to conduct effective crisis intervention. This is not always straightforward due to the bizarreness, vastness, and swiftly changing nature of the experience and requires sustained attentiveness and presence from the therapist(s). Techniques, Methods, and Interventions. The reviewed literature revealed a nondirective and supportive therapeutic framework is most commonly used during substance-assisted sessions (e.g.,. Preparation and integration sessions have more frequently incorporated therapeutic techniques and frameworks from motivational enhancement therapy (e.g.,, or cognitive behavioral therapy (CBT; for review, see. Anecdotal evidence suggests that initially, verbal communication may distract the client and could thus have fewer beneficial effects than expected in traditional talk therapy (particularly if high doses are administered;. Therapists may instead observe the client's facial expression and body language. If clients want to engage with the therapist(s), supportive listening and appropriate empathic responses are generally advised in the literature. After a few minutes, the therapist(s) may need to suggest the client resume an inward focus. If the suggestion is met with resistance, continued support and compassion may be offered until clients are ready to focus inward again. Resistance to an inward focus may represent experiential avoidance that should be discussed during integration sessions. In current studies with psilocybin, conventional psychotherapeutic techniques are usually not implemented until the last hour of the administration session. During later parts of the session, openness and receptiveness to the application of various therapeutic, meditative, breathwork, and bodywork methods may be increased (i.e., after peak effects of the substance begin to subside;. During challenging parts of the experience, reassurance, support, comfort, and connection through physical contact (i.e., reassurance by holding hands) may be initiated, if necessary, appropriate, and previously agreed on, after communication with the client. The therapist(s) may talk to the client through difficult parts of the experience and assess and acknowledge their emotions. Therapists ought to stay calm and reassure clients that they are safe and secure and that their current state of mind is the result of psychoactive substances that will wear off with time. Intense and unpleasant aspects of the experience should be acknowledged to convey empathy for the client; clients may be reminded to accept and surrender to the experience. Repeated suggestions and unconditional acceptance of the client's negative feelings in the substance-assisted session may challenge conditioned feelings of rejection and foster general acceptance. Attempts to distract the client from the intensity of the situation are likely to be counterproductive. If appropriate, certain techniques might be used to ease the tension and support the client: During times of heightened anxiety, several containment techniques can be borrowed from different therapeutic approaches, including relaxation techniques taught in CBT and Prolonged Exposure Therapy, and mindful diaphragmatic breathing. In their manual for psilocybin for depression using acceptance and commitment therapy (ACT),offer scripts for several grounding techniques including abdominal breathing, therapeutic touch, and body awareness exercises that are closely followed when participants experience distress. Generally, the client is encouraged to confront rather than avoid painful, difficult, or challenging affective states. In the case of further escalations, anxiolytic or antipsychotic medications may be administered, or, as a last resort, the client may be transferred to an emergency department. Research regarding different responses and interventions for challenging experiences is currently lacking. To conclude the session, clients might draw or paint as they desire. Alternatively, guided imagery has been used in later parts of the administration sessions in some studies.suggested that external symbolization might be used in the form of play therapy. By working through material that prompts internal conflicts, unconscious processes might be discharged in the form of hallucinations, and additional physical abreactions might occur. All emerging materials should be properly and continuously integrated. The efficacy of these techniques and methods has not yet been investigated in rigorous studies. Projection, Transference, and Countertransference.suggests that in SAPT transference aspects of the therapeutic relationship and strong emotional projections can be more pronounced than in regular psychotherapy. The intensity of transference may be proportional to resistance against facing the issues at hand. It is unclear whether transference situations in SAPT can or should be handled similar to transference in conventional psychotherapy. Due to the hallucinatory effects of some substances and the psychodynamicautobiographical experiences and symbolization, the usual misidentification (on the conceptual level) in transference may become amplified to complete identification (on the perceptual level) of the therapist(s) with different persons or entities. There have not been any investigations into whether the development and analysis of transference is essential for therapeutic progress in SAPT. It is suggested that the subjective experience of transference may vary widely. Several authors highlight that the therapist(s) is responsible for accepting and potentially dissolving the transferences and projections that may arise. The therapist(s) should aim to support the client throughout the issues and should be aware of their own reactions and potential counter-transferences. Related issues may include problems of authority, sexual tension, physical touch, client demands, and client wishes that need to be handled appropriately. If therapists are persuaded to act out instead of remaining centered, clients might be prevented from gaining insights. Therapists should seek supervision to reexamine their motivations and reactions and discuss and resolve these potential pitfalls. Projection, transference, and countertransference can be discussed with clients in the preparation phase (seeand it should be agreed that negative reactions from clients toward the therapist(s) will not be taken personally in the substance-assisted session. These phenomena may be regarded as normal and might become opportunities for the processing of unconscious material. Due to the heightened sensitivity to verbal and nonverbal expression under the influence of psychoactive substances in a dosing session, honest and open discussion about related feelings should be encouraged. A positive therapeutic relationship may alleviate disruptive transference reactions and facilitate working with these phenomena. The current evidence for the excessive occurrence of these phenomena in SAPT is anecdotal. Therapeutic Misconduct. One of the most frequently noted therapist issues is when unresolved problems within the therapist(s) become a burden for the client. Feelings of anxiety, helplessness, powerlessness, or disorientation may manifest as the therapist(s) not remaining grounded or becoming unable to provide a holding function. Likewise, there may be a risk of the therapist(s) feeling extraordinarily special, developing unhealthy grandiosity and narcissism, or adopting the role of a leader or guru instead of an equal human caretaker. As in conventional psychotherapy, therapists should resist any temptation to make the client dependent on them. Of greater concern are reported issues of sexual misconduct and unwanted sexual advances by therapists within SAPT sessions (e.g.,mer-maps-sponsored-investigators/). There is increased potential for these sexual boundary violations within SAPT sessions, due to the increased suggestiveness and vulnerability of clients under the influence of certain psychoactive substances. While experiential evidence suggests that some occasions of therapeutic touch (i.e., holding hands) can decrease clients' anxiety and offer support during challenging experiences, it is vital that any physical touch is nonsexual, used for support, and is explicitly discussed and consented to prior to administration. Therapists should remain aware of any sexual tension, but this should never be acted upon. and the acute effects of the substances have subsided, the therapist(s) may depart from the side of the therapy session. Clients usually stay overnight in a comfortable room with an attendant on duty. Alternatively, they may be picked up by a previously appointed and briefed companion. Clients are typically encouraged to reflect on the psychedelic experience once the therapist has concluded the substance-assisted session. They may be encouraged to write down or record creative expressions of their thoughts and the content of the session and subsequent experiences, dreams, and reflections. However, it has been noted that if the client remains severely anxious or reports suicidal intent, the therapist(s) ought to stay with the client overnight or consider hospitalization (only under extreme conditions;.
We conducted a systematized review and outlined information regarding appropriate conduct for therapists in administration sessions in SAPT. To the best of our knowledge, this is the first article to offer a systematic and comprehensive description of the evidentiary basis for current therapeutic conduct in administration sessions of SAPT. There seems to be a general agreement across sources regarding the overall process of the administration session and the rather unobtrusive and supportive stance of the therapist(s). Evidently, most of the information we extracted about therapeutic conduct in administration sessions was based on anecdotal evidence and research that was conducted before the Controlled Substances Act in 1970. While this evidence is valuable, recent clinical investigations of SAPT have offered only limited details on how administration sessions are conducted. Therefore, there is a pressing need for timelier and more rigorous qualitative and quantitative investigations to evaluate how specific therapeutic conduct during the administration sessions of SAPT affects therapeutic outcomes. Such studies would help to enhance the understanding of the mechanisms involved in the therapeutic benefits of SAPTs and further develop evidence-based practices in this area. One of the current gaps is the validation of optimal combinations of substances and doses for distinct conditions and disorders. Since the duration of the effects of the substances and their subjective effects differ dramatically, physicians and therapists need to be aware of the pharmacology and effects of different substances so they can suggest the bestsuited substance and dosage for their clients based on their experience, the treatment model, and therapeutic goals. Future research should also consider ethnoracial differences regarding the metabolism, safety, and efficacy of particular doses of these substancesas women, Black, Indigenous, and People of Color have been underrepresented in current investigations. Data do not address the therapeutic potential of the numerous derivatives of the substances included in this review, alone or in combination. Although their acute effects can mimic the symptoms of some target disorders (Garcia-Romeu & Richards, 2018), their novel pharmacological impact might have meaningful therapeutic advantages that could be explored in future studies. Current research does not offer conclusive information regarding the optimal number of sessions for specific substances and disorders. Future research should investigate potential links between the number of administration sessions and therapeutic outcomes. Recently, some authors suggested the number of sessions may be adapted to the clients' needs, the therapeutic goals, the therapeutic process, and the integration of the sessions. Although several studies explored the effects of music in SAPT, the results are not yet sufficient to form clear guidance. Most of the suggested key criteriahave not been investigated by rigorous research and currently lack a clear evidence base. While there was a consensus on the potential effects of music, the findings suggesting that this could be facilitative or unwelcome effects, future research is required to examine conditions that are likely to be most useful, potentially including personalized playlists. Scientific exploration of the value of different kinds of experiences is currently lacking. The data suggested that while the effects of psychoactive substances can be manifold and difficult to predict, some experiences may be more common than others. As such, it is important not to overgeneralize these descriptions of the experiences of individual people. Each session is unique and potentially influenced by the individual's life situation, biography, dispositions, and many other factors (see, for example,. Qualitative studies could explore the subjective effects clients may attribute to different kinds of experiences or the value of certain therapeutic interventions to handle them. Quantitative studies may investigate the links between the occurrence and intensity of certain experiences and therapeutic outcome measures. Rigorous research into therapists' characteristics and skills is lacking, as well. The evidence we retrieved for this review was largely anecdotal. Future research should explore the influence of therapists' ability to be present and responsive and the influence of their degree of self-awareness on the therapeutic relationship and the therapeutic outcome. Valid and reliable instruments to assess the perception of therapeutic presence in therapists and clients (e.g.,and therapeutic responsiveness (e.g.,exist and may be used in future studies (see. While the therapeutic techniques we identified may have positive effects in combination with a psychoactive substance, it is impossible to determine whether these effects are due to psychopharmacological effects of the substance, the therapy, or a combination of both. Most of the techniques we summarized are derived from anecdotal reports. Rigorous studies are needed to determine the efficacy of individual techniques, methods, and interventions. It has been proposed that the administration of psychedelics within nondirective and supportive contexts be compared with a structured and manualized CBT context to determine the impact of psychotherapy in SAPT. Others have suggested to systematically vary and compare the psychotherapy components in preparation, administration, and integration sessions. In addition, it would be informative to investigate whether the use of tools such as breathwork and meditation in later parts of the session may offer any benefits (e.g., improved short-term and longterm outcome measures) compared with controls who do not receive these interventions. Above that, investigating whether certain interventions (e.g., holding hands or breathing) for phases of heightened anxiety or other adverse effects are superior/quicker than others in resolving distress in clients (and thus improve therapeutic outcome) is vital. Furthermore, future research should explore whether projection and transference pose significant challenges in SAPT and how to best navigate these situations to inform future training programs for therapists. Reports of therapeutic misconduct, the potential perception of unequal power dynamics in the therapeutic relationship, and the fact that serotonergic psychedelics like LSD have been linked to increases in suggestibilityhighlight the need for a careful evaluation of current practices. Regulatory authorities must examine and, if necessary, handle professional misconduct. Supervision and peer review are important forums to reflect on challenging situations and prevent unethical behavior. Specific and repeated training must be implemented to increase therapists' ability to offer therapeutic support through consensual and appropriate therapeutic actions while avoiding encroaching behaviors. Future research should explore the specific challenges therapists face conducting therapy in substance-assisted settings. Qualitative investigations of adverse events and challenging situations for therapists are important to inform future training and supervision. In conclusion, it is evident that although clinical studies using SAPT for the treatment of various psychiatric disorders are steadily evolving, there has been limited research into the variables that potentially influence therapeutic outcomes. Most of the available evidence retrieved from the sources was anecdotal and based on untested philosophical and/or theoretical approaches. As a result, the effectiveness, risks, and essential components of therapeutic interventions remain largely tentative, necessitating systematic investigation to ensure optimal clinical outcomes. As such, conclusive statements regarding best practice during an administration session are not possible at this point. This comprehensive description of the current evidence base may be used to inform the baseline structures and future developments of SAPT training courses. It may also offer therapists interested in SAPT training a basis to evaluate the content of current programs. Future research should systematically investigate how specific therapeutic conduct during the administration sessions and certain experiences of the client affect therapeutic outcomes in SAPT. T. Wenge is a psychologist from Leipzig, Germany trained in gestalt therapy, systemic therapy, addiction therapy, trauma therapy, music therapy, and bonding psychotherapy. His professional and research interests focus on therapeutic community, attachment and autonomy, spirituality in psychotherapy, and substance-assisted psychotherapy. He is the former therapeutic director of an addiction clinic and currently works in psychosomatic clinics and private practice. He is the 1st Chairman of the German Society for Bonding Psychotherapy and board member of the International Society for Bonding Psychotherapy. S. J. Bright has worked as a psychologist within the mental health and AOD field for the past 15 years. He is currently senior lecturer of addiction at Edith Cowan University. He is a strong advocate of harm reduction and an evidence-based approach to AOD legislation. He is also interested in the role of certain substances (entheogens) to facilitate spiritual experiences and their role in psychotherapy.
Create a free account to open full-text PDFs.
Bogenschutz, M. P. · Current Drug Abuse Reviews (2013)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Belser, A. B. · Frontiers in Psychology (2022)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Diazgranados, N., Ibrahim, L., Brutsche, N. E. et al. · JAMA Psychiatry (2010)
Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)
Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M. et al. · Journal of Psychopharmacology (2021)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Kirchner, K. · Journal of Psychopharmacology (2014)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
Griffiths, R. R., Johnson, M. W. · Journal of Psychopharmacology (2016)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Holze, F., Duthaler, U., Vizeli, P. et al. · British Journal of Clinical Pharmacology (2019)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)
Johnson, M. W. · ACS Pharmacology and Translational Science (2020)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Kaelen, M., Barrett, F. S., Roseman, L. et al. · Psychopharmacology (2015)
Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)
Kaelen, M., Roseman, L., Kahan, J. et al. · European Neuropsychopharmacology (2016)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V. et al. · Journal of Psychoactive Drugs (2007)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Majic, T., Schmidt, T. T., Gallinat, J. · Journal of Clinical Psychopharmacology (2015)
Ross, S., Malone, T. C., Mennenga, S. E. et al. · Frontiers in Pharmacology (2018)
Mangini, M. · Journal of Psychoactive Drugs (2011)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A. et al. · Lancet Psychiatry (2018)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Moreno, F. A., Wiegand, C. B., Taitano, E. K. et al. · Journal of Clinical Psychiatry (2006)
Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)
Nicholas, C. R., Henriquez, K. M., Gassman, M. C. et al. · Journal of Psychopharmacology (2018)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Nichols, D. E. · Pharmacological Reviews (2016)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Oehen, P., Gasser, P. · Frontiers in Psychiatry (2022)
Palhano-Fontes, F., Barreto, D., Onias, H. et al. · Psychological Medicine (2018)
Passie, T., Halpern, J. H., Stichtenoth, D. O. et al. · CNS Neuroscience and Therapeutics (2008)
Passie, T., Seifert, J., Schneider, U. et al. · Addiction Biology (2002)
Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)
Phelps, J. · Journal of Humanistic Psychology (2017)
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Richards, W. A. · Journal of Humanistic Psychology (2016)
Richards, W. A., Rhead, J. C., Dileo, F. B. et al. · Journal of Psychedelic Drugs (1997)
Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Rucker, J., Iliff, J., Nutt, D. J. · Neuropharmacology (2017)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)
Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)
Sessa, B., Fischer, F. M. · Drug Science Policy and Law (2015)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
Strickland, J. C., Garcia-Romeu, A., Johnson, M. W. · ACS Pharmacology and Translational Science (2020)
Studerus, E., Gamma, A., Kometer, M. et al. · PLOS ONE (2012)
Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)
Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Nielson, E. M., Tai, S. J., Lennard-Jones, M. et al. · Frontiers in Psychiatry (2021)
Thal, S., Engels, L. B., Bright, S. J. · Journal of Humanistic Psychology (2022)
Thal, S. B., Wieberneit, M., Sharbanee, J. M. et al. · Journal of Psychopharmacology (2022)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)